The value of a drug: From innovation to the payment via karl marx

Journal of Ambulatory Care Management

Volumn 31, Issue 1, 2008, Pages 52-55

  Apolone, Giovanni ^a   Patarnello, Francesca ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; DRUG SCREENING; HUMAN; ITALY; PHILOSOPHY; POLITICAL SYSTEM; PUBLIC HEALTH; STANDARD; UNITED STATES;

DRUG EVALUATION; DRUGS, INVESTIGATIONAL; HUMANS; ITALY; NATIONAL HEALTH PROGRAMS; PHILOSOPHY; SOCIALISM; UNITED STATES;

EID: 37749008364     PISSN: 01489917     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JAC.0000304097.36334.aa     Document Type: Article

References (14)

1. Apolone, G., & Garattini, S. (2004). Drugs policy and market in Europe: A useful example for the USA. The Journal of Ambulatory Care Management, 27, 88.
2. Apolone, G., Joppi, R., Bettelè, V., & Garattini, S. (2005). Ten years of marketing approvals of anticancer drugs in Europe: Regulatory policy and guidance documents need to find a balance between different pressures. British Journal of Cancer, 93, 504-509.
3. Aronson, J. K. (2005). Drug development: More science, more education. British Journal of Clinical Pharmacology, 59, 317-318.
4. Attali, J. (2005, June 9). Karl Marx ou l'Esprit du monde. France: Fayard (Editions).
5. Bauman, Z. (1998, September 15). Globalization: The human consequences. New York: Columbia University Press.
6. Bauman, Z. (2005). Liquid life. Cambridge, England: Polity Press.
7. Bertelè, V., Banzi, R., Capasso, F., Taffuri, G., Trotta, F., Apolone, G., et al. (2007). Haematological anticancer drugs in Europe: Any added value at the time of approval? European Journal of Clinical Pharmacology, 63, 713-719.
8. ERICE Group. (2007). Eric statement on drug innovation (Letter to the Editors). British Journal of Clinical Pharmacology. DOI: 10.1111/j.1365-2125.2007.03033.x
9. Garattini, L., Cornago, D., & De Compadri, P. (2007). Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis. Health Policy, 82, 330-339.
10. IMS World Report on Drugs Sale. (2007). Intelligence.360 Global Pharmaceutical Perspectives 2006. Retrieved November 11, 2007, from http://www.imshealth.com
11. International Society of Drug Bulletins (ISDB). (2001, November 15-16). ISDB declaration on the therapeutic advances in the use of medicines. Paris: Author. Retrieved November 11, 2007, from http://www.icf.uab.es/ informacion/boletines/ISDB/ISDB.pdf
12. Joppi, R., Bettelè, V., &Garattini, S. (2005). Disappointing biotech. British Medical Journal, 331, 895-897.
13. Motola, P., De Ponti, F., Poluzzi, E., Martini, N., Rossi, P., Silvani, M. C., et al. (2006). An update of the first decade of the European centralized procedure: How many innovative drugs? British Journal of Clinical Pharmacology, 62, 610-616.
14. Pollack, A. (2007). Pricing pills by the results. New York Times. Retrieved November 11, 2007, from http://www.nytimes.com